First Quarter 2019 Net Sales of $17.6 million, Growth of 20% year over year

Provides 2019 Net Sales Outlook of $79 million to $83 million

SANTA BARBARA, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today its financial results for the first quarter ended March 31, 2019.

Jeff Nugent, Chairman and Chief Executive Officer of Sientra, commented, “In the first quarter, we continued to drive robust growth across both of our segments, achieving net sales of $17.6 million, a 20% increase compared to the year-ago period. This quarterly performance represents a solid start towards our 2019 objectives.”

Mr. Nugent added, “Our Breast Products segment grew net sales 14% year over year, strong evidence that we continue to gain market share. I am extremely proud of this accomplishment considering the media headwinds this category experienced in the first quarter. We were pleased with the FDA’s announcement last week confirming that all breast implant options remain safe and effective and will continue to be available in the United States. We are also excited about the FDA’s recent approval of our extra-high profile implants, which we expect to be a key addition to our breast reconstruction portfolio.”

Mr. Nugent concluded, “miraDry delivered another strong quarter, in spite of typical capital equipment seasonality, achieving net sales growth of 27% year over year. We fully scaled our marketing efforts in the first quarter based on the learnings from our 2018 pilots and launched our “No Sweat” global campaign. As our sales and marketing initiatives gain traction and drive increased brand awareness and market activation, I remain confident in the miraDry business model and believe the business is well-positioned to be a significant growth driver for Sientra in 2019 and beyond.”

First Quarter 2019 Financial Review

Total net sales for the first quarter 2019 were $17.6 million, an increase of 20% compared to total net sales of $14.7 million for the same period in 2018.

Net sales for the Breast Products segment totaled $9.8 million in the first quarter 2019, a 14% increase compared to $8.5 million for the same period 2018. Breast Products sales growth was primarily driven by new customer conversion programs and continued strong performance of the tissue expander portfolio.

Net sales for the miraDry segment totaled $7.8 million in the first quarter 2019, a 27% increase compared to $6.1 million for the same period 2018. miraDry sales growth was primarily driven by strong consumables growth internationally.

Gross profit for the first quarter 2019 was $11.1 million, or 63.1% of sales, compared to gross profit of $8.6 million, or 58.5% of sales, for the same period 2018. Changes in consolidated gross margin were driven by the overall mix between Breast Products and miraDry, as well as the geographic and capital versus consumable mix within miraDry.

Operating expenses for the first quarter 2019 were $36.9 million, compared to $27.5 million of expenses for the same period 2018. The growth in operating expenses was driven by increased investments in sales and marketing, higher stock based compensation, and one-time consulting fees associated with Sientra’s commercial initiatives.

Net loss for the first quarter 2019 was ($26.5) million, or ($0.91) per share, compared to a net loss of ($19.4) million, or ($0.99) per share, for the same period 2018.

On a non-GAAP basis, the Company reported an adjusted EBITDA loss of ($21.1) million compared to a loss of ($14.8) million for the same period 2018.

Net cash and cash equivalents as of March 31, 2019 were $62 million, compared to $87 million as of December 31, 2018. 

2019 Net Sales Outlook

For 2019, the Company expects net sales in the range of $79 million to $83 million, representing growth of 16% to 22% year-over-year, compared to net sales of $68.1 million in 2018.

2019 segment net sales outlook:

  • Breast Products net sales of $44 to $46 million
  • miraDry net sales of $35 to $37 million

Conference Call

Sientra will hold a conference call today, May 8, 2019 at 4:30 p.m. ET to discuss first quarter results.

The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 4982524. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at

A replay of the call will be available starting on May 8, 2019 at 7:30 p.m. ET through May 15, 2019 at 11:59 p.m. ET.  To access the replay, dial 855-859-2056 for domestic callers and 404-537-3406 for international callers and use the replay conference ID 4982524. The webcast will be available on the Investor Relations section of the Company’s website for 30 days following the completion of the call.  

Use of Non-GAAP Financial Measures

Sientra has supplemented its US GAAP net income (loss) with a non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company, facilitates a more meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP Adjusted EBITDA to GAAP net income (loss), the most directly comparable GAAP measure, is provided in the schedule below.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with Sientra’s financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS™ breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprises its miraDry® system, which is approved for sale in over 40 international markets, and is the only non-surgical FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.

(*) Data on file

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties.  Forward-looking statements include, but are not limited to, statements regarding the Company’s expected net sales for the year ended December 31, 2019, the expected growth of the Company’s current customer base and acquisition of new customers, the Company’s ability to achieve sustainable, long-term growth across its business segments, and the Company’s ability drive increased brand awareness and market activation. Such statements are subject to risks and uncertainties, including the dependence on conclusion of the review procedures for the quarter ended March 31, 2019 by the Company’s independent auditors, positive reaction from plastic surgeons and their patients to Sientra’s Breast Products, the ability to meet consumer demand, the acceptance and growth of its miraDry segment.  Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission.  All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

Sientra, Inc
Consolidated Statements of Operations
(In thousands, except per share and share amounts)
 Three Months Ended
 March 31, 
Net sales$17,552  $14,676 
Cost of goods sold 6,474   6,097 
Gross profit 11,078   8,579 
Operating expenses:   
Sales and marketing 20,401   15,256 
Research and development 3,054   2,751 
General and administrative 13,474   9,499 
Total operating expenses 36,929   27,506 
Loss from operations (25,851)  (18,927)
Other income (expense), net:   
Interest income 304   40 
Interest expense (952)  (655)
Other income (expense), net 15   119 
Total other income (expense), net (633)  (496)
Loss before income taxes (26,484)  (19,423)
Income tax (benefit) expense     
Net loss$(26,484) $(19,423)
Basic and diluted net loss per share attributable to common stockholders$(0.91) $(0.99)
Weighted average outstanding common shares used for net loss per share attributable to common stockholders:   
Basic and diluted 29,099,382   19,613,417 

Sientra, Inc
Condensed Consolidated Balance Sheets
(In thousands)
 March 31,  December 31,
 2019 2018
Current assets:   
Cash and cash equivalents$61,955 $86,899
Accounts receivable, net 24,767  22,527
Inventories, net 27,242  24,085
Prepaid expenses and other current assets 3,411  2,612
Total current assets 117,375  136,123
Property and equipment, net 3,146  2,536
Goodwill 12,507  12,507
Other intangible assets, net 15,915  16,495
Other assets 22,682  698
Total assets$171,625 $168,359
Liabilities and Stockholders' Equity   
Current liabilities:   
Current portion of long-term debt$12,998 $6,866
Accounts payable 15,109  13,184
Accrued and other current liabilities 30,416  27,697
Legal settlement payable   410
Customer deposits 10,892  9,936
Sales return liability 8,016  6,048
Total current liabilities 77,431  64,141
Long-term debt, net of current portion 24,416  27,883
Deferred and contingent consideration 6,531  6,481
Warranty reserve and other long-term liabilities 21,017  2,976
Total liabilities 129,395  101,481
Stockholders' equity:   
Total stockholders' equity 42,230  66,878
Total liabilities and stockholders' equity$171,625 $168,359


Sientra, Inc
Condensed Consolidated Statements of Cash Flows
(In thousands)
 Three Months Ended
 March 31, 
 2019 2018
Cash flows from operating activities:   
Net loss$(26,484) $(19,423)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation and amortization 831   880 
Provision for doubtful accounts 342   233 
Provision for warranties 273   183 
Provision for inventory 289   199 
Amortization of acquired inventory step-up    59 
Change in fair value of warrants (87)  (121)
Change in fair value of contingent consideration 185   621 
Change in deferred revenue 384   (99)
Amortization of debt discount and issuance costs 56   51 
Stock-based compensation expense 3,700   2,548 
Payments of contingent consideration liability in excess of acquisition-date fair value (630)   
Changes in assets and liabilities, net of effects from acquisitions:   
Accounts receivable (2,583)  (5,735)
Inventories (3,373)  (1,191)
Prepaid expenses, other current assets and other assets 396   (1,009)
Insurance recovery receivable    (10)
Accounts payable 1,853   4,684 
Accrued and other liabilities (2,312)  948 
Legal settlement payable (410)   
Customer deposits 956   8 
Sales return liability 1,968   4,400 
Net cash used in operating activities (24,646)  (12,774)
Cash flows from investing activities:   
Purchase of property and equipment (610)  (142)
Net cash used in investing activities (610)  (142)
Cash flows from financing activities:   
Proceeds from exercise of stock options 106    
Proceeds from issuance of common stock under ESPP 683   391 
Tax payments related to shares withheld for vested restricted stock units (RSUs) (2,725)  (1,296)
Gross borrowings under the Revolving Loan 4,183   9,033 
Repayment of the Revolving Loan (1,565)  (5,735)
Payments of contingent consideration up to acquisition-date fair value (370)   
Deferred financing costs    (6)
Net cash provided by financing activities 312   2,387 
Net decrease in cash, cash equivalents and restricted cash (24,944)  (10,529)
Cash, cash equivalents and restricted cash at:   
Beginning of period 87,242   26,931 
End of period$62,298  $16,402 
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets   
Cash and cash equivalents$61,955  $16,059 
Restricted cash included in other assets 343   343 
Total cash, cash equivalents and restricted cash$62,298  $16,402 


Sientra, Inc.
Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA
 Three Months Ended
 March 31, 
Dollars, in thousands 2019   2018 
Net loss, as reported$  (26,484) $  (19,423)
Adjustments to net loss:   
Interest (income) expense and other, net   633     496 
Depreciation and amortization   831     939 
Accretion in fair value adjustments to contingent consideration   185     621 
Stock-based compensation   3,700     2,548 
Total adjustments to net loss   5,349     4,604 
Adjusted EBITDA$  (21,135) $  (14,819)
 Three Months Ended
 March 31, 
As a Percentage of Revenue** 2019   2018 
Net loss, as reported (150.9%)  (132.3%)
Adjustments to net loss:   
Interest (income) expense and other, net 3.6%  3.4%
Depreciation and amortization 4.7%  6.4%
Accretion in fair value adjustments to contingent consideration 1.1%  4.2%
Stock-based compensation 21.1%  17.4%
Total adjustments to net loss 30.5%  31.4%
Adjusted EBITDA (120.4%)  (101.0%)
** Adjustments may not add to the total figure due to rounding